Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants With Stargardt Disease (STGD1) (CELESTE)

NCT07161544 is registered in ClinicalTrials.gov with AAVantgarde Bio Srl as lead sponsor.

NCT NCT07161544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07161544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants With Stargardt Disease (STGD1) (CELESTE)
Lead sponsor
AAVantgarde Bio Srl
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 29, 2025
Completion date
July 31, 2032
Enrollment
75 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

stargardt disease